Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pertuzumab

(per-TOO-zoo-mab)
A drug used with other drugs to treat breast cancer that is HER2 positive. It is used in patients whose cancer has spread to other parts of the body and has not already been treated with other anticancer drugs. It is also used before surgery in patients with locally advanced, inflammatory, or early-stage breast cancer and after surgery in patients with early-stage breast cancer who have a high risk that their cancer will recur (come back). It is also being studied in the treatment of other types of cancer. Pertuzumab binds to a protein called HER2, which is found on some cancer cells. Blocking this protein may help kill cancer cells. Pertuzumab is a type of monoclonal antibody. Also called Perjeta.
More Information
Search NCI's Dictionary of Cancer Terms